Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2022

View Archived Issues

HCAR2 targeting modulates the progression of AD in mice

IRF3 orchestrates obesity-induced inflammation and dysglycemia

Inhaled bispecific single-domain antibody neutralizes multiple SARS-CoV-2 variants

Allosteric regulators targeting GCase decrease toxic substrate accumulation in models of GD

Novel carbazole derivatives attenuate mitochondrial function in models of lung adenocarcinoma

Chengdu Origiant Pharmaceutical patents RIPK1 inhibitors

Guangzhou Maxinovel Pharmaceuticals discloses PD-1/PD-L1 interaction inhibitors

Betta Pharmaceuticals presents new CD73 inhibitors

J2H Biotech identifies new PROTACs for NSCLC

Compass Pathfinder synthesizes new safrylamine derivatives

LUM-015 shows potential for imaging of inflammatory protease activity in atherosclerosis

Tollovir and Tollovid show 3CL protease inhibition in vitro against Omicron SARS-CoV-2 variants

Aligos selects broad-spectrum coronavirus protease inhibitor ALG-097558 for advancement

CARB-X option funding supports Clarametyx's development of anti-biofilm therapy CMTX-101

Plasma desmosine is a prognostic factor in acute myocardial infarction

TEM1 is a marker of heart failure severity

Gut reaction to rapamycin extends female fly lifespan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...